Rezolute’s Ersodetug Shows Promise in Tumor HI but Faces FDA Hurdles…

Event summary

Rezolute’s Phase 3 upLIFT study for tumor HI shows 7 out of 8 participants meeting the primary endpoint, with topline results expected before year-end 2026.
Phase 3 sunRIZE study for congenital HI did not meet its primary endpoint, with data still under FDA review.
Cash reserves declined to $107.8 million as of June 30, 2026, from $167.9 million a year earlier.
R&D expenses decreased to $53.8 million in fiscal 2026 from $61.5 million in fiscal 2025, while G&A expenses increased to $29.2 million from $18.4 million.

The big picture

Rezolute’s progress in tumor HI with ersodetug is promising, but the setback in congenital HI and ongoing FDA review introduce regulatory risks. The company’s financials reflect a strategic shift towards cost management amid clinical development challenges. The broader biotech sector continues to grapple with regulatory hurdles and the need for sustained investment in rare disease therapies.

What we're watching

Regulatory Headwinds: Whether the FDA will accept the sunRIZE study data for congenital HI or require a new randomized control trial.
Clinical Execution: The pace at which Rezolute can complete enrollment and announce topline results for the upLIFT study in tumor HI.
Financial Sustainability: How Rezolute will manage its declining cash reserves while preparing for potential commercial activities.